

Abstract

The present invention provides a fusion protein, comprising: a) a ligand that stimulates cancer cell growth and corresponds to receptors overexpressed by cancer cells, or a screened peptide that is affinitive to or antagonist to cancer cell receptors, or a peptide that directly interacts with cancer cell surface; b) a superantigen that may lead to anti-cancer immune response. It also discloses expression vectors and host cells comprising this fusion protein, methods for preparing this fusion protein, and the application of this fusion protein to prepare therapeutic agents for cancer or immune disease treatment.